Literature DB >> 17661438

A journey in structure-based drug discovery: from designed peptides to protein surface topomimetics as antibiotic and antiangiogenic agents.

Ruud P M Dings1, Kevin H Mayo.   

Abstract

Most biological events are mediated through molecular interactions by proteins, and because proteins are composed of structural units like helices, beta-sheets and turns, small peptides and peptidomimetics may be used to mimic their biological effects and even as therapeutic agents in the clinic. Here, we present a structure-based, scaffold-driven approach to design bioactive peptides and peptidomimetics. Initially, we designed a novel series of beta-sheet-forming peptides that mimic the activities of both antibiotic bacterial membrane disrupting peptides and antiangiogenic proteins. We subsequently used structure-activity relationships to reduce the design to partial peptide mimetics and then to fully nonpeptide topomimetics. Some of these agents are currently in extensive preclinical studies for further development as drug candidates against infectious disease and cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17661438     DOI: 10.1021/ar700086k

Source DB:  PubMed          Journal:  Acc Chem Res        ISSN: 0001-4842            Impact factor:   22.384


  19 in total

1.  Microbeam radiation therapy alters vascular architecture and tumor oxygenation and is enhanced by a galectin-1 targeted anti-angiogenic peptide.

Authors:  Robert J Griffin; Nathan A Koonce; Ruud P M Dings; Eric Siegel; Eduardo G Moros; Elke Bräuer-Krisch; Peter M Corry
Journal:  Radiat Res       Date:  2012-05-18       Impact factor: 2.841

2.  Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1.

Authors:  Ruud P M Dings; Nigam Kumar; Michelle C Miller; Melissa Loren; Huzaifa Rangwala; Thomas R Hoye; Kevin H Mayo
Journal:  J Pharmacol Exp Ther       Date:  2012-12-11       Impact factor: 4.030

3.  Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer.

Authors:  Ruud P M Dings; Kieng B Vang; Karolien Castermans; Flavia Popescu; Yan Zhang; Mirjam G A Oude Egbrink; Matthew F Mescher; Michael A Farrar; Arjan W Griffioen; Kevin H Mayo
Journal:  Clin Cancer Res       Date:  2011-01-20       Impact factor: 12.531

4.  Galectin-1-based tumour-targeting for gold nanostructure-mediated photothermal therapy.

Authors:  Samir V Jenkins; Dmitry A Nedosekin; Emily K Miller; Vladimir P Zharov; Ruud P M Dings; Jingyi Chen; Robert J Griffin
Journal:  Int J Hyperthermia       Date:  2017-05-09       Impact factor: 3.914

5.  Synthesis of Norbornane Bisether Antibiotics via Silver-mediated Alkylation.

Authors:  Shane M Hickey; Trent D Ashton; Jonathan M White; Jian Li; Roger L Nation; Heidi Y Yu; Alysha G Elliott; Mark S Butler; Johnny X Huang; Matthew A Cooper; Frederick M Pfeffer
Journal:  RSC Adv       Date:  2015       Impact factor: 3.361

6.  Surface binding inhibitors of the SCF-KIT protein-protein interaction.

Authors:  David Margulies; Yarden Opatowsky; Steven Fletcher; Ishu Saraogi; Lun K Tsou; Sourav Saha; Irit Lax; Joseph Schlessinger; Andrew D Hamilton
Journal:  Chembiochem       Date:  2009-08-17       Impact factor: 3.164

7.  Bacterial membrane disrupting dodecapeptide SC4 improves survival of mice challenged with Pseudomonas aeruginosa.

Authors:  Ruud P M Dings; Judith R Haseman; Dan B Leslie; Mike Luong; David L Dunn; Kevin H Mayo
Journal:  Biochim Biophys Acta       Date:  2013-02-09

8.  Inhibitory mechanism of peptides with a repeating hydrophobic and hydrophilic residue pattern on interleukin-10.

Authors:  Guoying Ni; Yuejian Wang; Scott Cummins; Shelley Walton; Kate Mounsey; Xiaosong Liu; Ming Q Wei; Tianfang Wang
Journal:  Hum Vaccin Immunother       Date:  2016-09-29       Impact factor: 3.452

9.  Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer.

Authors:  Ruud P M Dings; Joseph I Levine; Susan G Brown; Lucile Astorgues-Xerri; John R MacDonald; Thomas R Hoye; Eric Raymond; Kevin H Mayo
Journal:  Invest New Drugs       Date:  2013-02-08       Impact factor: 3.850

10.  Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven.

Authors:  Ruud P M Dings; Emily S Van Laar; Jeremy Webber; Yan Zhang; Robert J Griffin; Stephen J Waters; John R MacDonald; Kevin H Mayo
Journal:  Cancer Lett       Date:  2008-04-01       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.